Optimal drug therapy

PreclinicalSmall molecule

Optimal drug therapy is one of 5 small molecule programs targeting Parkinson's Disease (PD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's Disease (PD)Completed

Parkinson's Disease (PD)Preclinical

Completed

Competition

Competitive Landscape

8 competitors in Parkinson's Disease (PD)

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

TJ0113

HHangzhou PhecdaMed Co., Ltd.

Phase 3

1 3

AAV2-Haadc

KKrzysztof Bankiewicz

Phase 1

1 4

Buntanetap/posiphen

AAnnovis Bio Inc.

Preclinical

1 5

Optimal drug therapy

VVanderbilt University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)

Completed·VVanderbilt University Medical Center·N/A·NCT00282152·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Optimal drug therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Optimal drug therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Optimal drug therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt University Medical Center

Optimal drug therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

References

Drug Info

Quick Facts

Related News